Scholar Rock Holding Corporation is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts. The company focuses on discovering and developing targeted biologic medicines that modulate the transforming growth factor-beta (TGF-β) superfamily of cell proteins. Its proprietary platform is designed to selectively target the precursor, or latent, forms of growth factors to address the underlying biology of various diseases. Scholar Rock's lead clinical candidate, apitegromab, is a muscle-targeted monoclonal antibody being developed to improve motor function in patients with spinal muscular atrophy (SMA) and to preserve lean mass in obesity treatments. Additionally, the company is advancing SRK-181, a selective inhibitor of latent TGF-β1 activation, for the treatment of checkpoint-resistant solid tumors. As a clinical-stage entity, Scholar Rock does not yet generate commercial product revenue and relies on capital markets and strategic partnerships to fund its research and development activities.
